{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:16:02Z","timestamp":1790266562350,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1124\/jpet.119.260869","type":"journal-article","created":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T21:05:41Z","timestamp":1570050341000},"page":"692-702","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["A Novel Phosphodiesterase 1 Inhibitor DSR-141562 Exhibits Efficacies in Animal Models for Positive, Negative, and Cognitive Symptoms Associated with Schizophrenia"],"prefix":"10.1016","volume":"371","author":[{"given":"Takeshi","family":"Enomoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Tatara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Goda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Nishizato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kantaro","family":"Nishigori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mami","family":"Kamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiori","family":"Taga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.119.260869_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0014-2999(90)90240-7","article-title":"Discriminatory roles for D1 and D2 dopamine receptor subtypes in the in vivo control of neostriatal cyclic GMP","volume":"181","author":"Altar","year":"1990","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.119.260869_bib2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.biopsych.2015.12.028","article-title":"Novel dopamine therapeutics for cognitive deficits in schizophrenia","volume":"81","author":"Arnsten","year":"2017","journal-title":"Biol Psychiatry"},{"key":"10.1124\/jpet.119.260869_bib3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.bbr.2015.03.025","article-title":"The serotonin 5-HT1A receptor agonist tandospirone improves executive function in common marmosets","volume":"287","author":"Baba","year":"2015","journal-title":"Behav Brain Res"},{"key":"10.1124\/jpet.119.260869_bib4","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/pr.58.3.5","article-title":"Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use","volume":"58","author":"Bender","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1124\/jpet.119.260869_bib5","doi-asserted-by":"crossref","DOI":"10.1093\/cercor\/bhz041","article-title":"Phosphodiesterase 1 bridges glutamate inputs with NO- and dopamine-induced cyclic nucleotide signals in the striatum","author":"Betolngar","year":"2019","journal-title":"Cereb Cortex"},{"key":"10.1124\/jpet.119.260869_bib6","doi-asserted-by":"crossref","first-page":"e2569","DOI":"10.1002\/hup.2569","article-title":"A phase I, randomized, proof-of-clinical-mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers","volume":"32","author":"Boland","year":"2017","journal-title":"Hum Psychopharmacol"},{"key":"10.1124\/jpet.119.260869_bib7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1192\/S0007125000293574","article-title":"A glutamatergic deficiency model of schizophrenia","volume":"37","author":"Carlsson","year":"1999","journal-title":"Br J Psychiatry Suppl"},{"key":"10.1124\/jpet.119.260869_bib8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1192\/S0007125000298292","article-title":"Extrapyramidal syndromes and new antipsychotic drugs: findings in patients and non-human primate models","volume":"29","author":"Casey","year":"1996","journal-title":"Br J Psychiatry Suppl"},{"key":"10.1124\/jpet.119.260869_bib9","doi-asserted-by":"crossref","first-page":"104471","DOI":"10.1016\/j.neuint.2019.104471","article-title":"Effect of phosphodiesterase (1B, 2A, 9A and 10A) inhibitors on central nervous system cyclic nucleotide levels in rats and mice","volume":"129","author":"Chen","year":"2019","journal-title":"Neurochem Int"},{"key":"10.1124\/jpet.119.260869_bib10","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1136\/bmj.280.6207.66","article-title":"Molecular pathology of schizophrenia: more than one disease process?","volume":"280","author":"Crow","year":"1980","journal-title":"BMJ"},{"key":"10.1124\/jpet.119.260869_bib11","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1037\/0735-7044.103.3.526","article-title":"Successful performance by monkeys with lesions of the hippocampal formation on AB and object retrieval, two tasks that mark developmental changes in human infants","volume":"103","author":"Diamond","year":"1989","journal-title":"Behav Neurosci"},{"key":"10.1124\/jpet.119.260869_bib12","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1021\/acs.jmedchem.7b00302","article-title":"Discovery of selective phosphodiesterase 1 inhibitors with memory enhancing properties","volume":"60","author":"Dyck","year":"2017","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.119.260869_bib13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1358\/mf.2007.29.4.1075358","article-title":"Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis","volume":"29","author":"Enomoto","year":"2007","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"10.1124\/jpet.119.260869_bib14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jpsychires.2018.07.006","article-title":"The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: a critical and comprehensive review","volume":"108","author":"Girgis","year":"2019","journal-title":"J Psychiatr Res"},{"key":"10.1124\/jpet.119.260869_bib15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1089\/adt.2008.135","article-title":"Scintillation proximity assays in high-throughput screening","volume":"6","author":"Glickman","year":"2008","journal-title":"Assay Drug Dev Technol"},{"key":"10.1124\/jpet.119.260869_bib16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00213-004-1793-y","article-title":"Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction","volume":"174","author":"Goldman-Rakic","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.119.260869_bib17","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s40268-017-0214-8","article-title":"A randomized multiple dose pharmacokinetic study of a novel PDE10A inhibitor TAK-063 in subjects with stable schizophrenia and Japanese subjects and modeling of exposure relationships to adverse events","volume":"17","author":"Goldsmith","year":"2017","journal-title":"Drugs R D"},{"key":"10.1124\/jpet.119.260869_bib18","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1124\/jpet.109.155994","article-title":"Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia","volume":"331","author":"Grauer","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.260869_bib19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bbr.2012.09.030","article-title":"D1 receptor agonists reverse the subchronic phencyclidine (PCP)-induced novel object recognition (NOR) deficit in female rats","volume":"238","author":"Horiguchi","year":"2013","journal-title":"Behav Brain Res"},{"key":"10.1124\/jpet.119.260869_bib20","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1007\/s00213-017-4587-8","article-title":"Phosphodiesterase-1b (Pde1b) knockout mice are resistant to forced swim and tail suspension induced immobility and show upregulation of Pde10a","volume":"234","author":"Hufgard","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.119.260869_bib21","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/gbb.12391","article-title":"Phosphodiesterase-1b deletion confers depression-like behavioral resistance separate from stress-related effects in mice","volume":"16","author":"Hufgard","year":"2017","journal-title":"Genes Brain Behav"},{"key":"10.1124\/jpet.119.260869_bib22","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.260869_bib23","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"Javitt","year":"1991","journal-title":"Am J Psychiatry"},{"key":"10.1124\/jpet.119.260869_bib24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0893-133X(98)00060-8","article-title":"The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia","volume":"20","author":"Jentsch","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.119.260869_bib25","series-title":"Animal and Translational Models for CNS Drug Discovery","first-page":"199","article-title":"Developing new drugs for schizophrenia: from animals to the clinic","author":"Jones","year":"2008"},{"key":"10.1124\/jpet.119.260869_bib26","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/nm.3935","article-title":"Modeling psychiatric disorders for developing effective treatments","volume":"21","author":"Kaiser","year":"2015","journal-title":"Nat Med"},{"key":"10.1124\/jpet.119.260869_bib27","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cellsig.2013.10.007","article-title":"Select 3\u2032,5\u2032-cyclic nucleotide phosphodiesterases exhibit altered expression in the aged rodent brain","volume":"26","author":"Kelly","year":"2014","journal-title":"Cell Signal"},{"key":"10.1124\/jpet.119.260869_bib28","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1111\/bph.14034","article-title":"PDE1A inhibition elicits cGMP-dependent relaxation of rat mesenteric arteries","volume":"174","author":"Khammy","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.119.260869_bib29","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1124\/jpet.111.191353","article-title":"Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo","volume":"341","author":"Kleiman","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.260869_bib30","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.bbr.2016.02.031","article-title":"The atypical antipsychotic blonanserin reverses (+)-PD-128907- and ketamine-induced deficit in executive function in common marmosets","volume":"305","author":"Kotani","year":"2016","journal-title":"Behav Brain Res"},{"key":"10.1124\/jpet.119.260869_bib31","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00406-018-0869-3","article-title":"Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis","volume":"268","author":"Krause","year":"2018","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1124\/jpet.119.260869_bib32","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.neuropharm.2010.05.004","article-title":"Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues","volume":"59","author":"Lakics","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.119.260869_bib33","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/sj.npp.1301563","article-title":"Neuroplasticity of neocortical circuits in schizophrenia","volume":"33","author":"Lewis","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.119.260869_bib34","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1021\/acs.jmedchem.5b01751","article-title":"Discovery of potent and selective inhibitors of phosphodiesterase 1 for the treatment of cognitive impairment associated with neurodegenerative and neuropsychiatric diseases","volume":"59","author":"Li","year":"2016","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.119.260869_bib35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.neuropharm.2015.10.037","article-title":"Biochemical and behavioral effects of PDE10A inhibitors: relationship to target site occupancy","volume":"102","author":"Li","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.119.260869_bib36","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394C(T) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1124\/jpet.119.260869_bib37","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1096\/fj.02-0681fje","article-title":"Microarray analysis of nonhuman primates: validation of experimental models in neurological disorders","volume":"17","author":"Marvanov\u00e1","year":"2003","journal-title":"FASEB J"},{"key":"10.1124\/jpet.119.260869_bib38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fnmol.2019.00021","article-title":"Phosphodiesterase 1b (PDE1B) regulates spatial and contextual memory in hippocampus","volume":"12","author":"McQuown","year":"2019","journal-title":"Front Mol Neurosci"},{"key":"10.1124\/jpet.119.260869_bib39","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bbr.2013.02.019","article-title":"Effects of lurasidone on executive function in common marmosets","volume":"246","author":"Murai","year":"2013","journal-title":"Behav Brain Res"},{"key":"10.1124\/jpet.119.260869_bib40","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0014-2999(84)90453-9","article-title":"Sex-dependent differences in the pharmacological actions and pharmacokinetics of phencyclidine in rats","volume":"97","author":"Nabeshima","year":"1984","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.119.260869_bib41","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1254\/jphs.10R01FM","article-title":"Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: biochemical and behavioral profiles of phosphodiesterase inhibition in dopaminergic neurotransmission","volume":"114","author":"Nishi","year":"2010","journal-title":"J Pharmacol Sci"},{"key":"10.1124\/jpet.119.260869_bib42","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1161\/01.RES.0000256354.95791.f1","article-title":"Overview of PDEs and their regulation","volume":"100","author":"Omori","year":"2007","journal-title":"Circ Res"},{"key":"10.1124\/jpet.119.260869_bib43","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1111\/bph.14350","article-title":"Targeting the dopamine D1 receptor or its downstream signalling by inhibiting phosphodiesterase-1 improves cognitive performance","volume":"175","author":"Pekcec","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.119.260869_bib44","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1523\/JNEUROSCI.14-03-01251.1994","article-title":"Expression of a calmodulin-dependent phosphodiesterase isoform (PDE1B1) correlates with brain regions having extensive dopaminergic innervation","volume":"14","author":"Polli","year":"1994","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.119.260869_bib45","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00001756-200101220-00010","article-title":"Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment","volume":"12","author":"Qiao","year":"2001","journal-title":"Neuroreport"},{"key":"10.1124\/jpet.119.260869_bib46","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1523\/JNEUROSCI.22-12-05188.2002","article-title":"Phosphodiesterase 1B knock-out mice exhibit exaggerated locomotor hyperactivity and DARPP-32 phosphorylation in response to dopamine agonists and display impaired spatial learning","volume":"22","author":"Reed","year":"2002","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.119.260869_bib47","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1586\/ern.10.191","article-title":"Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment","volume":"11","author":"Remington","year":"2011","journal-title":"Expert Rev Neurother"},{"key":"10.1124\/jpet.119.260869_bib48","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00213-008-1273-x","article-title":"Selective phosphodiesterase inhibitors: a promising target for cognition enhancement","volume":"202","author":"Reneerkens","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.119.260869_bib49","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1515\/REVNEURO.1999.10.1.59","article-title":"Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity","volume":"10","author":"Sams-Dodd","year":"1999","journal-title":"Rev Neurosci"},{"key":"10.1124\/jpet.119.260869_bib50","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1124\/jpet.107.132910","article-title":"Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia","volume":"325","author":"Schmidt","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.260869_bib51","series-title":"Cognition in Schizophrenia: Impairments, Importance, and Treatment Strategies","author":"Sharma","year":"2000"},{"key":"10.1124\/jpet.119.260869_bib52","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.schres.2015.11.015","article-title":"An emerging role of cGMP in the treatment of schizophrenia: a review","volume":"170","author":"Shim","year":"2016","journal-title":"Schizophr Res"},{"key":"10.1124\/jpet.119.260869_bib53","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.neuropharm.2007.04.009","article-title":"Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-1B (PDE1B) enzyme","volume":"53","author":"Siuciak","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.119.260869_bib54","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1007\/s00213-016-4346-2","article-title":"Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats","volume":"233","author":"Snyder","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.119.260869_bib55","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.2174\/1381612819666131216115417","article-title":"Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment","volume":"20","author":"Snyder","year":"2014","journal-title":"Curr Pharm Des"},{"key":"10.1124\/jpet.119.260869_bib56","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.neuropharm.2009.09.008","article-title":"Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A","volume":"58","author":"Strick","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.119.260869_bib57","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1021\/ml300372f","article-title":"Discovery of novel N-substituted oxindoles as selective M1 and M4 muscarinic acetylcholine receptors partial agonists","volume":"4","author":"Sumiyoshi","year":"2013","journal-title":"ACS Med Chem Lett"},{"key":"10.1124\/jpet.119.260869_bib58","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbr.2006.10.029","article-title":"Influence of gender on working and spatial memory in the novel object recognition task in the rat","volume":"177","author":"Sutcliffe","year":"2007","journal-title":"Behav Brain Res"},{"key":"10.1124\/jpet.119.260869_bib59","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1021\/bi00778a018","article-title":"Multiple cyclic nucleotide phosphodiesterase activities from rat brain","volume":"10","author":"Thompson","year":"1971","journal-title":"Biochemistry"},{"key":"10.1124\/jpet.119.260869_bib60","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuropharm.2013.10.015","article-title":"Phosphodiesterase 10A inhibitor MP-10 effects in primates: comparison with risperidone and mechanistic implications","volume":"77","author":"Uthayathas","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.119.260869_bib61","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1046\/j.0953-816x.2001.01546.x","article-title":"Dissociable contributions of the orbitofrontal and lateral prefrontal cortex of the marmoset to performance on a detour reaching task","volume":"13","author":"Wallis","year":"2001","journal-title":"Eur J Neurosci"},{"key":"10.1124\/jpet.119.260869_bib62","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/978-3-319-58811-7_13","article-title":"Phosphodiesterase 1: a unique drug target for degenerative diseases and cognitive dysfunction","volume":"17","author":"Wennogle","year":"2017","journal-title":"Adv Neurobiol"},{"key":"10.1124\/jpet.119.260869_bib63","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0306-4522(97)00075-4","article-title":"Contrasting effects of excitotoxic lesions of the prefrontal cortex on the behavioural response to D-amphetamine and presynaptic and postsynaptic measures of striatal dopamine function in monkeys","volume":"80","author":"Wilkinson","year":"1997","journal-title":"Neuroscience"},{"key":"10.1124\/jpet.119.260869_bib64","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1017\/S146114570500516X","article-title":"A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia","volume":"8","author":"Woodward","year":"2005","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1124\/jpet.119.260869_bib65","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1523\/JNEUROSCI.14-03-00973.1994","article-title":"Differential expression of the 61 kDa and 63 kDa calmodulin-dependent phosphodiesterases in the mouse brain","volume":"14","author":"Yan","year":"1994","journal-title":"J Neurosci"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524268452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524268452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.119.260869","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:57:27Z","timestamp":1739973447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524268452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0022356524268452"],"URL":"https:\/\/doi.org\/10.1124\/jpet.119.260869","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Novel Phosphodiesterase 1 Inhibitor DSR-141562 Exhibits Efficacies in Animal Models for Positive, Negative, and Cognitive Symptoms Associated with Schizophrenia","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.119.260869","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}